Health
Lilly Cuts Outlook After Obesity Drug Sales Post First Miss
- Company cites inventory problems at wholesalers in sales miss
- Drugmaker cuts top of full-year sales guidance by $600 million
This article is for subscribers only.
Eli Lilly & Co. lowered guidance Wednesday on lackluster sales of its weight-loss drug, which posted a shocking first miss that raised questions about the seemingly insatiable demand for the shots.
Listen to the Here’s Why podcast on Apple, Spotify or anywhere you listen.